Landos Biopharma Reports Fourth Quarter and Full Year 2021

Continued Progress Towards Optimizing Clinical Development Plans On Track to Initiate Phase 2b Study of Omilancor in Ulcerative Colitis Later this Year ...

Related Keywords

China ,Roger Adsett ,Landos Biopharma ,Chris Garabedian ,Tim Mayleben ,Development Expenses ,Clinical Development Updates ,Landos Biopharma Inc ,Progress Towards Optimizing Clinical Development ,Nasdaq ,Initiate Phase ,Ulcerative Colitis Later ,Ulcerative Colitis ,Normal Healthy Volunteers ,Top Line Results ,Both Studies Expected ,Interim President ,Landos Board ,Fourth Quarter ,Full Year ,Cash Equivalents ,Marketable Securities ,Administrative Expenses ,Nasdaq Labp ,Nc ,